WASHINGTON, Aug. 19 -- The U.S. Department of Health and Human Services Food and Drug Administration issued the following warning letter to Safrel Pharmaceuticals LLC from its Center for Drug Evaluation and Research: * * * Recipient: Mr. Dipen Patel, Chief Executive Officer, Safrel Pharmaceuticals LLC, 178 Ridge Road, Dayton, NJ 08810-2532, United States Issuing Office: Center for Drug Evaluation and Research (CDER), United States Warning Letter 320-26-111 Dear Mr. Patel: The United States  more